MNMD241220P15000
- 8.59
- 0.000.00%
Mind Medicine Newsroom
Mind Medicine Price Target Announced at $20.00/Share by Chardan Capital
Mind Medicine Initiated at Buy by Chardan Capital
MindMed To Be Added To The Nasdaq Biotechnology Index, Effective At Market Open On December 23, 2024
MindMed to Be Added to the Nasdaq Biotechnology Index
Mind Medicine Analyst Ratings
Oppenheimer Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $20
Mind Medicine (MNMD) Receives a Buy From Oppenheimer
Mind Medicine Doses First Patient in Phase 3 Study of MM120 to Treat Generalized Anxiety Disorder
Express News | Mind Medicine (MindMed) Inc - Panorama Study to Initiate in U.S. and Europe in First Half of 2025
Express News | MindMed Announces First Patient Dosed in Phase 3 Voyage Study of Mm120 in Generalized Anxiety Disorder (Gad)
MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress
MindMed Awarded Innovation Passport Designation By United Kingdom Innovative Licensing And Access Pathway Steering Group For MM120 Orally Disintegrating Tablet For Generalized Anxiety Disorder
Express News | Mind Medicine: Awarded Innovation Passport Designation by UK Ilap Steering Group for Mm120 Odt for Generalized Anxiety Disorder
MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)
Express News | MindMed Appoints Javier Muniz, M.d., as Vice President of Research and Development Strategy
MindMed Announces New Employee Inducement Grants
RBC Capital Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $21
RBC Capital Remains a Buy on Mind Medicine (MNMD)
MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer
Is Mind Medicine (MNMD) the Best Multibagger Stock to Buy Heading Into 2025?